Author/Authors :
Ibrahim، Abeer نويسنده Department of Medical Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Assiut, Egypt , , Amin، Anwar T نويسنده Department of Surgical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt , , Hassan، Rehab نويسنده Department of Medical Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Assiut, Egypt ,
Abstract :
Background: Preoperative determination of the extent of viable residual tumor is
an important issue after neoadjuvant treatment. On the other hand, retrospective data
suggest that breast-conserving surgery is feasible up to stage IIIA breast cancer without
preoperative therapy.
Methods: We retrospectively analyzed 164 patients who underwent breastconserving
surgery followed by adjuvant chemotherapy and/or endocrinal therapy with
whole breast radiation between 2005 and 2012. Of those, 116 patients had stages I and
II (group 1) breast cancer, whereas 48 patients had stage IIIA (group 2).
Results:After a median follow-up of 40.4 months, 18 (15.5%) patients in group-
1and 8 (16.6%) in group-2 developed ipsilateral breast tumor recurrence (P=0.77). Mean
time to tumor recurrence was 19 months in group 1 and 17 months in group 2 (P=0.5).
However we found more ipsilateral breast tumor recurrence in hormone negative
tumors (P=0.002), high grade tumors (P=0.021), young age (P=0.017) and lymph node
positive cases (P=0.011). We observed no significant difference between N1 and N2
lymph node status (P=0.241).
Conclusion: Our data suggest that breast-conserving surgery with R0 resection is
feasible in stage IIIA cases whenever cosmetic appearance can be maintained as long
as surgery will be followed by radiotherapy and chemotherapy. A prospective study with
larger numbers is recommended for further evaluation of this issue.